CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer

Sara Cabrero-de las Heras, Eva Martínez-Balibrea

Sara Cabrero-de las Heras, Eva Martínez-Balibrea, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, Germans Trias i Pujol health research institute, Badalona, Barcelona 08916, Catalunya, Spain

Sara Cabrero-de las Heras, Eva Martínez-Balibrea, Program of Predictive and Personalized Cancer Medicine, Germans Trias i Pujol health research institute, Badalona, Barcelona 08916, Catalunya, Spain

ORCID number: Sara Cabrero-de las Heras (0000-0002-9364-5371); Eva Martínez-Balibrea (0000-0002-4501-7100).

Author contributions: Both authors contributed equally to the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and approval of the final version.

Supported by the Institute of Health Carlos III (ISCIII), No. PI16/01800 and PIE16/00011.

Conflict-of-interest statement: The authors declare no potential conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: July 5, 2018
Peer-review started: July 5, 2018
First decision: August 25, 2018
Revised: September 27, 2018
Accepted: October 16, 2018
Article in press: October 16, 2018
Published online: November 14, 2018

Abstract

Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women, worldwide. In the early stages of the disease, biomarkers predicting early relapse would improve survival rates. In metastatic patients, the use of predictive biomarkers could potentially result in more personalized treatments and better outcomes. The CXC family of chemokines (CXCL1 to 17) are small (8 to 10 kDa) secreted proteins that attract neutrophils and lymphocytes. These chemokines signal through chemokine receptors (CXCR) 1 to 8. Several studies have reported that these chemokines and their receptors have a role in either the promotion or inhibition of cancer, depending on their capacity to suppress or stimulate the action of the immune system, respectively. In general terms, activation of the CXCR1/CXCR2 pathway or the CXCR4/CXCR7 pathway is associated with tumor aggressiveness and poor prognosis; therefore, the specific inhibition of these receptors is a possible therapeutic strategy. On the other hand, the lesser known CXCR3 and CXCR5 axes are generally considered to be tumor suppressor signaling pathways, and their stimulation has been suggested as a way to fight cancer. These pathways have been studied in tumor tissues (using immunohistochemistry or measuring mRNA levels) or serum [using enzyme-linked immuno sorbent assay (ELISA) or multiplexing techniques], among other sample types. Common variants in genes encoding for the CXC chemokines have also been investigated as possible biomarkers of the disease. This review summarizes the...
most recent findings on the role of CXC chemokines and their receptors in CRC and discusses their possible value as prognostic or predictive biomarkers as well as the possibility of targeting them as a therapeutic strategy.

**Key words:** Biomarkers; Treatment; Chemotherapy; Oxaliplatin; Irinotecan; Immunotherapy; Colorectal cancer; CXC chemokines; Immune system; Bevacizumab

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The contribution of the immune system to the development and progression of cancer is now fully acknowledged. The specific action of the immune system depends on the type of immune cells that are recruited to the tumor sites. Chemokines from the CXC subfamily are released by tumor cells and cells within the tumor microenvironment, whereupon they attract cells with anti-tumor (e.g., CD4+ and CD8+ lymphocytes) or pro-tumor activity (e.g., myeloid-derived suppressor cells). Chemokines have been proposed as prognostic factors, as biomarkers of response to therapy and as drug targets. The present review addresses the most recent findings in the field.

INTRODUCTION

Colorectal cancer (CRC) is the third most common type of cancer worldwide, representing approximately 10% of all diagnosed cancers, and it is the most frequent cause of cancer-related deaths. In Europe, the prognosis of localized disease is quite good; the 5-year overall survival rates are near 90%; however, in patients with regional or distant disease, these rates drop to 70% and down to 20%, respectively. One of the main reasons behind this poor survival rate is that, in almost all cases, tumors become resistant to therapy. Therefore, it is necessary to find useful and reliable predictive biomarkers that allow physicians to assign effective drugs specific to each case. In general, the current first-line treatment for metastatic CRC (mCRC) is based upon combinations of chemotherapy [fluoropyrimidines, oxaliplatin (OXA) and/or irinotecan], consisting of doublets (FOLFOX or FOLFIRI) or triplets (FOLFOXIRI) in specific cases, and rational molecularly targeting agents [anti-epidermal growth factor receptor (anti-EGFR), cetuximab or panitumumab; anti-vascular endothelial growth factor (anti-VEGF), bevacizumab]. Mutations in the RAS and BRAF family of oncogenes are indicative of the inefficacy of anti-EGFR drugs and are the only predictive markers available currently. The recent classification of CRC into four molecular subtypes has shed light on the biology of this tumor. However, the clinical usefulness and application of this classification is still under discussion.

It has been proposed that serum levels of certain chemokines may be used as predictive markers for the response to chemotherapy. The CXC family of chemokines and their receptors are crucial for inflammation and antitumor immunity, which are key factors in CRC progression. These small proteins are secreted not only by tumor cells but also by leukocytes, fibroblasts, endothelial cells and epithelial cells. They modulate tumor behavior by regulating angiogenesis, activating tumor-specific immune responses and directly stimulating tumor proliferation in an autocrine or paracrine fashion. The CXC family of chemokines and receptors have been associated with metastasis and resistance to treatment. Several studies have reported the expression of CXC chemokines and/or their receptors in tumors (in epithelial tumor cells, fibroblasts or infiltrating leukocytes) or in plasma/serum samples from CRC patients, and this expression has been associated with patient outcomes. Furthermore, the CXC genes are highly polymorphic, and certain genetic variants have been associated with prognosis and response to treatment. The aim of the present work is to review the literature and discuss the possible use of the CXC family of chemokines as predictive or prognostic markers in CRC (Table 1). We will focus on the main pathways that are activated after the appropriate chemokines bind to the receptors CXCR1, CXCR2, CXCR4, CXCR7, CXCR3, CXCR5, CXCR6 and CXCR8.

LITERATURE SEARCH

We established the work of Verbeke et al as reference from which we searched the literature. We used PubMed as the primary source to find all of the articles published on this topic. The following keywords were employed in the search: chemokine/s, resistance, CRC, chemotherapy, 5 fluorouracil, OXA, cetuximab, bevacizumab, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL16, CXCL17, CXCR1, CXCR2, CXCR4, CXCR2 inhibitor, CXCR4 inhibitor, repaarin, cancer, repertaxin, and plerixafor. In addition to PubMed, we also performed a brief Google search for “Chemokine CRC.”

THE CXC FAMILY OF CHEMOKINES

CXC chemokines are small proteins; CXC refers to the location of the two cysteine residues near the N-terminal, with the X representing any amino acid (cysteine-
containing motif)\(^9\). These chemokines can be subclassified based on the presence or absence of the tripeptide motif (Glu-Leu-Arg at the NH\(_2\) terminus) as ELR\(^+\) or ELR\(^-\), respectively. The ELR\(^+\) chemokines are considered to be angiogenic, whereas the ELR\(^-\) chemokines are considered to be angiostatic\(^10,12\). Nevertheless, contradictory results have been published, which we will discuss in the present review.

CXC chemokines are named according to their original function, and they also follow the standard nomenclature CXCL\(_x\), where the L stands for “ligand” and the \(x\) corresponds to a number (Table 2). To exert their function, chemokines bind to their cognate CXCR which, in the majority of cases, is a 7-transmembrane G protein-coupled receptor\(^13\). After binding, the receptors change their conformation and activate the coupled G protein, initiating the corresponding signaling pathway. Only a few of the CXCRs are atypical receptors, which are not coupled to a G protein but to beta-arrestins; these receptors include the atypical chemokine receptor 3 (ACKR3) also known as CXCR7\(^14\). Certain chemokines can bind to more than one receptor and vice versa, as is the case for the promiscuous CXCR2\(^15\) (Table 2). After a given CXCL binds and activates the corresponding CXCR, the receptor is usually internalized through clathrin-mediated endocytosis for further degradation or recycling.
All four chemokines have been found to be upregulated in CRC [21]. One of the most relevant studies demonstrating the role of CXCL1 and 2 in treatment resistance and metastasis was performed by the group of Joan Massagué. This group showed that CXCL1 and CXCL2 are overexpressed in breast cancer cells that are primed for survival in metastatic sites. These two chemokines attract CD11b⁺Gr1⁺ myeloid cells which, in turn, produce more chemokines and enhance cancer cell survival. Regarding chemoresistance, this group found that chemotherapeutic agents, such as 5 Fluorouracil (5FU), doxorubicin hydrochloride, cyclophosphamide monohydrate and paclitaxel trigger a stromal reaction, leading to TNF-α production. TNF-α increases CXCL1/2 expression via NF-κB, which results in a feedback loop that promotes cancer cell survival [17]. NF-κB is a transcription factor that can be activated downstream of the PKB/AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Increased activity of NF-κB has been associated with the high expression of genes to the plasma membrane [16] (Figure 1).

Originally, the role of these chemokines and their receptors was associated with inflammatory processes wherein leukocytes accumulate in injured or infected tissues. Given that inflammation is a hallmark of cancer, it is not surprising that once in the nucleus, the CXC chemokines exert their activity through various pathways, such as tumor necrosis factor alpha (TNF-α)/nuclear factor κB (NF-κB) and protein kinase B (PKB/AKT) [17,18]. These pathways are related to survival, proliferation, angiogenesis, pathological processes such as tumor growth and metastasis [19,20], and even responses to anticancer treatments (Figure 2).

**AXIS 1: CXCR1 AND CXCR2**

The CXCR1/CXCR2 pathway is the most widely studied pathway in cancer. CXCL1, 2, 3 and 8 are proangiogenic and chemoattractive chemokines that all bind to the receptor CXCR2, for which CXCL1 has the highest affinity. All four chemokines have been found to be upregulated in CRC [21]. One of the most relevant studies demonstrating the role of CXCL1 and 2 in treatment resistance and metastasis was performed by the group of Joan Massagué. This group showed that CXCL1 and CXCL2 are overexpressed in breast cancer cells that are primed for survival in metastatic sites. These two chemokines attract CD11b⁺Gr1⁺ myeloid cells which, in turn, produce more chemokines and enhance cancer cell survival. Regarding chemoresistance, this group found that chemotherapeutic agents, such as 5 Fluorouracil (5FU), doxorubicin hydrochloride, cyclophosphamide monohydrate and paclitaxel trigger a stromal reaction, leading to TNF-α production. TNF-α increases CXCL1/2 expression via NF-κB, which results in a feedback loop that promotes cancer cell survival [17]. NF-κB is a transcription factor that can be activated downstream of the PKB/AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Increased activity of NF-κB has been associated with the high expression of genes...
related to cancer cell survival, proliferation, angiogenesis, and also the development of resistance to anticancer drugs (Figure 2). As CXCL1 and 2 (and other chemokines that bind to CXCR1 and 2) can activate this pathway, it is not surprising that these chemokines play a role in chemoresistance and may also serve as predictive biomarkers in CRC.

For instance, we reported that CRC cells with acquired resistance to OXA exhibited high intracellular and secreted levels of CXCL1, 2 and 8, which was a consequence of the upregulated activation of NF-κB in the resistant cells. Both the inhibition of NF-κB with curcumin and the silencing of genes encoding for these chemokines led to a partial reversion of the resistance phenotype. The combination of curcumin and OXA was especially synergistic in resistant cells. Moreover, in experiments with tissue explants derived from hepatic CRC metastasis, we determined that higher levels of CXCL1 led to higher sensitivity of explants to the combination of curcumin + OXA. Thus, the tumor or serum levels of CXCL1 may serve as a useful biomarker for OXA resistance and may be indicative of curcumin + OXA sensitivity[18]. In another study, Ning et al[22] reported that CXCL8 mediated resistance to OXA in CRC cell lines through its binding to CXCR2 and AKT/MAPK/NF-κB signaling. The gene silencing of CXCR2 sensitized cells to the platinum drug. Treatment of CRC cell lines with a CXCR2 antagonist (SCH-527123) resulted in decreased migration and invasion, and increased apoptosis, acting synergistically with OXA. Further work performed in vivo
demonstrated similar results[23]. These results, together with those reported by Wilson et al[23] in prostate cancer cells, suggest that the levels of at least CXCL1 and 8 (and also CXCR2) can identify CRC patients who are unlikely to respond to OXA, who may be putative candidates for treatment with CXCR2 inhibitors in combination with this platinum agent.

The role of the CXCR1/CXCR2 pathway in the response and resistance to chemotherapy is not limited to OXA. Due to the role of these chemokines and receptors in promoting angiogenesis, it has been speculated that they can influence the response and resistance to antiangiogenic drugs. Two works reported that low serum levels of CXCL8 in mCRC patients treated with chemotherapy plus bevacizumab had better outcomes. First, in a short communication from Abajo et al[23], low levels of CXCL8 measured before treatment with bevacizumab, irinotecan and gemcitabine, were associated with better response rates in a small cohort of patients. This group also reported a general decrease in the levels of CXCL8 in post-treatment samples[25]. In another study, Di Salvatore et al[26] analyzed the serum levels of CXCL8 in 120 RAS mutant patients treated with first-line 5FU + Leucovorin + OXA (known as FOLFOX) + bevacizumab. They found that low levels of CXCL8 were associated with longer progression-free (PFS) and overall survival (OS). The same group also studied a polymorphism (c-251T>A) in the CXCL8 gene and reported that the TT genotype was associated with lower PFS and OS in the aforementioned patients but not in another cohort that was treated only with FOLFOX. Interestingly, patients carrying the TT genotype had significantly lower serum levels of CXCL8 compared with patients with the AT or AA genotype[26]. Another polymorphism (rs2234671) in the CXCR1 gene was found to be associated with the overall response rate in 132 mCRC patients treated with OXA-based chemotherapy plus bevacizumab. However, the authors did not provide a biological explanation underlying these results[25].

Two methods of measuring chemokines and their receptors include the immunohistochemical staining of proteins in tumor tissues and the qPCR evaluation of mRNA levels. Using these techniques, Desurmont et al[28] determined that high levels of CXCR2 and its ligands, CXCL7 and 8, were associated with worse PFS and OS in CRC patients who underwent neoadjuvant chemotherapy (different schedules) followed by metastatic hepatectomy, but not in those who were treated with surgery alone. CXCR2 and CXCL7 mRNA levels were higher in metastasis from chemotherapy-treated patients compared to metastasis from patients who underwent surgery alone. These data suggest not only the prognostic value of CXCR2 (and CXCL7) but also its involvement in disease aggressiveness. Therefore, targeting the CXCR1/2-mediated signaling pathway has been suggested as a possible therapeutic approach for treating CRC and other tumors.

As the CXCR1/2-mediated signaling pathway is associated with inflammation, several studies have described how the inhibition of CXCR1 or CXCR2 could potentially be used for preventive purposes[20-31]. Notably, the study by Jamieson et al[31] showed that CXCR2 acts as a potent pro-tumorigenic CXCR which directs the recruitment of tumor-promoting leukocytes into tissues (including the intestines) during tumor-induced and tumor-driven inflammation. Thus, the deletion or inhibition of this receptor led to the profound suppression of inflammation-driven and spontaneous tumorigenesis in a mouse model of colon cancer, suggesting that CXCR2 antagonists may have therapeutic and prophylactic potential in the treatment of cancer[31]. Additionally, in the metastatic setting, it has been shown that treatment with inhibitors of this pathway may be a good strategy[23,32-34]. Interestingly, the use of two different inhibitors against CXCR1 and 2 reduced the development of metastasis in mouse models but had no effect on primary tumors. This effect was due, in part, to the capacity of the inhibitors to abrogate neovascularization[35].

**AXIS 2: CXCR4 AND CXCR7**

The CXCR4/CXCR7 pathway is activated after the binding of CXCL12 to CXCR4 or 7. Strikingly, although CXCL12 is an ELR chemokine, the activity of this pathway has been primarily associated with stemness, the development of metastasis and poor prognosis. CXCR4 has been shown to co-localize with CRC stem cell markers, such as Lgr5, CD133 and CD44, and this co-localization was associated with epithelial-mesenchymal transition (EMT) processes and resistance to therapy[35-38]. Similar to CXCR1/2, the NF-κB transcription factor appears to have a role in the induction of EMT. In this case, it has been shown that lipopolysaccharides can promote the migratory capacity of CRC in vivo and in vitro by inducing CXCR4 expression and EMT through NF-κB signaling[39]. Additionally, the link between obesity and CRC has been attributed to the interaction between the adipokine visfatin and CXCL12[40]. CXCR4 expression appears to be increased in tumors compared with normal tissues and in metastasis compared with primary tumors. This increase is associated with poor prognosis, as shown in the work by Yopp et al[41]. This group assessed CXCR4 (among other factors) expression by immunohistochemical staining in 75 patients who underwent partial hepatectomy with curative intention and found that CXCR4 positivity was negatively associated with disease-specific and recurrence-free survival[41]. This finding suggests the possibility of targeting CXCR4 for therapeutic purposes. A lentiviral vector carrying siRNA targeting CXCR4 was used in CRC cell lines and a mouse model; the result was a reduction in cell proliferation, migration and invasion and the formation of hepatic metastasis[42]. Other researchers are attempting to exploit the membrane localization of CXCR4 to direct nanoparticles that recognize this receptor, facilitating their entry into the cells to deliver antineoplastic drugs[43]. Specific inhibitors, such as plerixafor, have been identified as a possible therapy for CRC and are under investigation in several clinical trials.
involving solid and non-solid tumors. Regardless of the strategy, it is important to take into account the biology of CXCR4 and 7. Two studies reported inconsistent regulation and effects between these two receptors. Romain et al.\textsuperscript{44} reported elevated levels of both receptors in late stage carcinomas compared to normal mucosa, colon polyps or early carcinomas. However, this group demonstrated that while CXCR4 expression was strongly induced by hypoxia-inducible factor 1 alpha (HIF-1α), this was not the case of CXCR7. Moreover, the reduction of CXCR4 expression was associated with a decrease in AKT and extracellular signal-regulated kinases (ERK) activation which, was not observed for CXCR7. The authors conclude that CXCR4 is a more promising target compared to CXCR7 in CRC\textsuperscript{44}. Similarly, Heckmann and colleagues showed different (and partly antidromic) patterns of expression between CXCR7 and CXCR4 after stimulation with CXCL12 in colon cancer cells. CXCR4 overexpression was associated with increased levels of microRNA-217 and -218 in CXCR4-overexpressing cells, but this was not the case for the overexpression of CXCR7. Additionally, CXCR4 cells were more sensitive to 5FU compared with CXCR7 cells\textsuperscript{65}. Thus, the clinical application of CXCR4 antagonists, such as plerixafor, should be studied with caution. Finally, the relationship between this pathway and the resistance to treatment of CRC has also been studied. High levels of CXCR4 were found to be associated with resistance to all chemotherapeutic agents used (5FU, irinotecan and OXA), including anti-VEGF therapies. In SW1116 colon cancer cells with acquired resistance to OXA or 5FU, the expression of and signaling through CXCR4 was found to be associated with the chemoresistant phenotype. Specifically, the authors demonstrated that the ERK1/2/MAPK and phosphatidylinositol-3-kinases (PI3K)/AKT pathway was important in CXCR4-mediated chemoresistance\textsuperscript{46}. The effect of CXCR4 on resistance to OXA can be exploited therapeutically by using endostar, a modified endostatin. When endostar and OXA are administered together, they have a synergistic effect, primarily due to the reduction in CXCR4 levels\textsuperscript{47}. In two different orthotopic mouse models, treatment with anti-VEGFR2 therapy resulted in the upregulation of both CXCL12 and CXCR4. CXCR4-expressing immunosuppressive innate immune cells (Ly6low monocytes) were recruited to the tumor site upon treatment with anti-VEGFR2, which was abrogated after CXCR4 blockade\textsuperscript{48}.

**AXIS 3: CXCR3**

The chemokines CXCL4, CXCL9, CXCL10 and CXCL11 are considered to exert an angiostatic effect through their binding to CXCR3, although CXCL11 can also bind to CXCR7\textsuperscript{49}. CXCR3 is found on peripheral blood activated T cells in vitro and on a significant fraction of circulating CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells, B cells and natural killer (NK) cells, but not on monocytes or neutrophils\textsuperscript{50}. These chemokines are upregulated by interferon gamma (IFN-γ) and, therefore, they have important roles in inflammatory diseases, such as ulcerative colitis\textsuperscript{50} and active pulmonary tuberculosis\textsuperscript{51}. However, the infiltration of activated CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells in tumors is considered to be a good prognostic factor; consequently, most of the research on the expression of these chemokines or their receptors in the context of CRC is focused in that direction. An interesting study by Lal et al.\textsuperscript{52} suggests that KRAS mutations are associated with reduced levels of CXCL10 and with the suppression of cytotoxic T cells, neutrophils and the IFN-γ pathway, especially in CRC consensus molecular subtype (CMS) 2 and CMS3. Other studies also reported the potential of these chemokines as good prognostic factors, primarily because of their association with the high infiltration of CD8\textsuperscript{+} T and CD4\textsuperscript{+} T helper 1 (Th1) effector cells\textsuperscript{53-55}. Mice injected with colonic tumor cells overexpressing CXCL10 were protected against metastasis development\textsuperscript{52}. Two independent studies demonstrated the post-surgical positive prognostic value of CXCL10 expression in localized colon cancer\textsuperscript{53,56}. Specifically, in the study by Agesen et al.\textsuperscript{57}, CXCL10 levels were part of a 13-gene expression classifier called ColoGuideEX for the prognosis prediction in stage II CRC. Interestingly, some authors have reported the opposite results. For instance, a high level of CXCR3 protein expression in primary CRC tumors was shown to be indicative of a poor prognosis\textsuperscript{57}. In another study, the authors investigated the molecular factors underlying the poor prognosis of CRC tumor neuroendocrine differentiation and found that neuroendocrine-like cells secreted high levels of CXCL10 and CXCL11 which, in turn, promoted the recruitment of tumor-associated macrophages, thereby promoting the proliferation and invasion of CRC cells and leading to a poor prognosis\textsuperscript{58}.

Taken together, these findings appear to indicate that targeting CXCR3 or its ligands would not be an effective therapeutic strategy against CRC. However, some authors have speculated otherwise about the possibility of enhancing this pathway indirectly. It is worth commenting on three different papers that address three different strategies. First, Brackett et al.\textsuperscript{59} used a Toll-like receptor 5 (TLR5) agonist called entolimod in a murine mCRC model. This group found that entolimod induced the expression of CXCL9 and CXCL10 in tumors which, in turn, led to the recruitment of CXCR3+ NK cells to the liver, thereby activating dendritic cells (DCs) and stimulating the CD8\textsuperscript{+} T cell response. Consequently, the drug exerted an anti-metastatic effect and a tumor-specific and durable immune memory\textsuperscript{59}. Second, Yang et al.\textsuperscript{60} studied the effect of signal transducer and activator transcription 3 (STAT3) inhibition in combination with immunogenic chemotherapy (anthracyclines). This group showed that, when injected in mice, STAT3 KO cells developed tumors with higher infiltration of DCs and cytotoxic T cells after treatment with anthracyclines. These tumors also displayed higher levels of CXCL9 and 10. Consequently, STAT3 inhibition improved the outcome of chemotherapy-treated mice by synergizing with immunogenic chemotherapy\textsuperscript{60}. Another interesting
approach involved the depletion of regulatory T cells (Treg) in mice bearing CRC tumors. This depletion was associated with an increase in T cell infiltration and proliferation and an increase in CXCL9 and 10, which led to the accumulation of CXCR3 T cells and the increased mRNA expression of IFN-γ, which suggests Treg cell targeting as a possible anti-tumor immunotherapy.[61]. It is important to note that some studies have indicated that CXCR3 targeting may be a good strategy against CRC cancer.[62,63]

Finally, high mRNA levels of CXCL9 and 11[64] as well as CXCL10[64,65] appear to be associated with the response to neoadjuvant chemotherapy (5FU) plus radiotherapy in patients with locally advanced rectal cancer; on the other hand, CXCL4 was shown to be upregulated after treatment with 5FU, which was associated with accelerated growth in vivo.[66]. These studies suggest the possibility of using members of this pathway as predictive biomarkers.

**AXIS 4: MISCELLANY**

Finally, it is worth commenting on the lesser known chemokines CXCL13, 16 and 17. Similar to that of the previously mentioned chemokines, the CXCL13-CXCR5 axis is involved in regulating lymphocyte migration and promoting inflammation.[67]. However, the role of this axis in promoting or inhibiting tumor development or progression is not clear, as the current articles report contradictory results. Zhu et al.[68] reported that this pathway promotes the growth, migration and invasion of colon cancer cells, likely through the PI3K/AKT pathway. Accordingly, high plasma levels of CXCL13 and positive immunohistochemical staining of CXCL13 and CXCR5 in tumors from CRC patients were associated with clinical and pathological characteristics typically related with a worse prognosis[69,70]. In contrast, high levels of CXCL13 in colorectal tumors have also been shown to be associated with the infiltration of follicular Th and B cells and, consequently, with a better prognosis. Cremonesi et al.[71] attributed the increase in CXCL13 levels to the presence of gut microbiota, whereas in the work of Bindea et al.[72], genomic instability affected CXCL13 expression, which led to alterations in T and B cell infiltration and clinical outcomes. In addition, it appears that a significant CD8+ T cell subset in colorectal tumors that are CXCR5+ potentially contribute to anti-tumor activity.[73]. Not surprisingly, low levels of CXCL13 have been reported as a negative prognostic factor in CRC patients.[66,74]. These contradictory results may be affected by several factors, including tumor stage, treatment, molecular subtype and microsatellite instability.

CXCR6 is expressed on the surface of CD4+ T cells, CD8+ T cells, NK cells and plasma cells and is responsible for inducing the chemotactic migration of these cells to inflamed tissues. The ligand of CXCR6, CXCL16, has two forms, the trans-membrane (TM) form and the soluble(s) form. TM-CXCL16 is expressed on macrophages, DCs, monocytes, and B cells where it functions as a cell adhesion molecule for cells that express CXCR6[75]. TM-CXCL16 is also a novel scavenger receptor that binds to phosphatidylserine and oxidized lipoprotein. In the membrane, this chemokine is cleaved by the disintegrin-like metalloproteinases ADAM10 and ADAM17, producing fragments that are released outside the cells[76]. sCXCL16 functions as a chemotactic factor for CXCR6-expressing Th1, T cells and NK cells. Interestingly, soluble CXCL16 can promote angiogenesis in human umbilical vein endothelial cells[77]. Again, given its capacity to promote tumor immunity, many of the published works describe CXCL16 as a positive prognostic factor.[78-80]. On the other hand, Matsushita et al.[81] reported that CRC patients had higher levels of CXCL16 in the serum compared to healthy controls, and these levels increased with tumor stage and were correlated with poor survival. In patients with localized disease, higher serum levels of CXCL16 were associated with a higher probability of metachronous liver recurrence and worse survival. In vitro, treatment with recombinant CXCL16 promoted cell growth, migration, invasion and EMT[81]. Thus, the exact role of CXCL16 in CRC warrants further investigation.

Finally, CXCL17 is a 119-amino acid CXC chemokine that binds specifically to CXCR8[82,83]. This chemokine is expressed in breast and colon cancer and acts as a chemotactic factor for monocytes, macrophages and mature and immature DCs, thereby playing an important role in angiogenesis[84-86]. CXCL17 expression is co-regulated with VEGF expression[82,84] and can attract neutrophils to tumor sites and promote tumorigenesis through angiogenesis in mouse models[86]. Very little is known about the role of CXCL17 in CRC. Ohlsson et al.[87] reported high mRNA levels of CXCL17 in several CRC cell lines as well as very high mRNA and protein levels of CXCL17 in primary CRC tumors compared to normal colon tissue. CXCL17-positive cells measured by immunofluorescence and immunohistochemistry were significantly more abundant in colon cancer tissues (80%) compared with the controls (normal colon samples from proximal or distal resection margin). Interestingly, CXCL17 was more abundant in tumor epithelial cells (17.2%) in comparison with tumor stromal cells (2.7%), and CXCL17 mRNA levels were correlated with the myeloid cell marker CD68, which is primarily expressed in antigen presenting cells (APCs), suggesting that this chemokine may contribute to the infiltration of APCs into the tumor[87]. Taken together, these findings indicate that the high expression of CXCL17 in CRC may be an indicator of poor prognosis in colon cancer, although further studies are warranted to elucidate the exact role of this chemokine in this malignancy.

In summary, very little information is available on the role of these less-known chemokines in CRC development or response to treatment.

**CONCLUSION**

The importance of the immune system in the surveil- lance, prognosis and treatment of cancer is undeniable.
The recent development of immunotherapies and the rapidness of their application to the clinics for several tumor types demonstrate the possibilities of exploiting the immune system as a target for drug development. Moreover, the recent publication of the international validation of the consensus Immunoscore® [8] as a reliable tool to classify colon cancer and to prognosticate its outcome also reveals the utility of using immune factors (in this case, total tumor-infiltrating T cell (CD3+)) and cytotoxic T cell counts (CD8+) as biomarkers. Therefore, other immune system-related factors thought to be important in cancer development and/or progression may also serve as prognostic and/or predictive biomarkers. Specially, those soluble factors that are released from tumor cells and are involved in the attraction of tumor-promoting or -killing cells are interesting candidates.

In the present review, we have described the potential utility of chemokines from the CXCL family as biomarkers of response and prognosis in CRC. Moreover, as these chemokines exert their function through binding to membrane receptors, these receptors also appear to be excellent drug targets. Some challenges still need to be overcome. First, some researchers have doubts about the systemic value of a factor that exerts its function locally. Second, due to certain contradictory reports, a deeper knowledge of the exact roles of each chemokine and its receptor(s) is urgently needed. Nevertheless, we are convinced that in the following years, these small secreted proteins will have a large role in predictive and personalized cancer medicine.

REFERENCES

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-271 [PMID: 24890451 DOI: 10.3322/caac.21235]

2. Welch HG, Robertson DJ. Colorectal Cancer on the Decline--Why Screening Can’t Explain It All. N Engl J Med 2016; 374: 1605-1607 [PMID: 27119236 DOI: 10.1056/NEJMmp1600448]

3. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van de Velde CJ, De Vos J, Vermeulen L, Guinney J, Kopetz S, Tejpar S. The role of CXCL chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 2012; 1825: 117-129 [PMID: 22079531 DOI: 10.1016/j.bbcan.2011.10.008]

4. Cabrero-de las Heras S, et al. CXC chemokines in CRC.
Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. *Int J Cancer* 2011; 128: 2038-2049 [PMID: 20648559 DOI: 10.1002/ijc.25562]

Ying Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagalappali Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. *Mod Cancer Ther* 2012; 11: 1353-1364 [DOI: 10.1158/1535-7163.MCT-11-0915]

Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O’ Sullivan JM, Wilson RH, Johnston PG, Waugh DJ. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. *J Pharmacol Exp Ther* 2008; 327: 746-759 [PMID: 18780829 DOI: 10.1124/jpet.108.143826]

Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N. Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer. *J Pathol* 2017; 241: 558-648 [PMID: 28026241 DOI: 10.1002/path.4868]

Wu W, Cao J, Ji Z, Wang J, Jiang T, Ding H. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer. *Oncotarget* 2016; 7: 81144-81155 [PMID: 27835894 DOI: 10.18632/oncotarget.13214]

Zhu P, Zhao N, Sheng D, Hou J, Hao C, Yang X, Zhu B, Zhang S, Han Z, Wei L, Zhang L. Inhibition of Growth and Metastasis of Colon Cancer by Delivering 5-Fluorouracil-loaded Pluronic F85 Copolymer Micelles. *Sci Rep* 2016; 6: 20896 [PMID: 26664651 DOI: 10.1038/srep20896]

Cutler MJ, Lowthers EL, Richard CL, Hadijuck DM, Spagnuolo PA, Blay J. Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptide CD26. *BMC Cancer* 2015; 15: 882 [PMID: 26552750 DOI: 10.1186/s12885-015-1702-2]

Margolin DA, Silinsky J, Grimes C, Spencer N, Aycock M, Green H, Cordova J, Davis NK, Driscoll T, Li L. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling. *Neoplasia* 2011; 13: 874-886 [PMID: 21969820]

Liu WT, Jing YY, Yan F, Han ZP, Lai FB, Zeng JX, Yu GF, Fan QM, Li R, Zhao QD, Wu MC, Wei LX. LPS-induced CXCR4-dependent migratory properties and a mesenchymal-like phenotype of colorectal cancer cells. *Cell Adh Migr* 2017; 11: 13-23 [DOI: 10.1080/19336981.2015.1134404]

Huang WS, Chen CN, Sze CT, Teng CC. Viscatin induces stromal cell-derived factor-1 expression by β1 integrin signaling in colorectal cancer cells. *J Cell Physiol* 2013; 228: 1017-1024 [PMID: 23042611DOI: 10.1002/jcp.24248]

Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, DeMatteo RP, D’Angelica MI. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. *Ann Surg Oncol* 2012; 19 Suppl 3: S339-S346 [PMID: 21584832 DOI: 10.1245/s10434-011-1774-4]

West GB, Hsu BG, Liu DW, Shi HP, Dong WG. The influence of lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of colorectal cancer. *Int J Oncol* 2014; 44: 1861-1869 [PMID: 24647809 DOI: 10.3892/ijo.2014.2348]

Unzueta U, Céspedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero JL, Domingo-Espin J, Villaverde A, Mangues R, Vázquez E. Intracellular CXCR4 cell targeting with T22-empowered protein-only nanoparticles. *Int J Nanomedicine* 2012; 7: 4533-4544 [PMID: 22923991 DOI: 10.2147/IJN.S34450]

Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreac E, Guenot D. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. *Mol Cancer* 2014; 13: 58 [PMID: 24629239 DOI: 10.1186/1476-4598-13-58]

Heckmann D, Maier P, Lauß S, Li L, Sleeman JP, Trunk MJ, Leopold H, Wenz F, Zeller WJ, Fruehauf S, Allgayer H. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. *Clin Cancer Res* 2014; 20: 604-616 [PMID: 24255072 DOI: 10.1158/1078-0432.CCR-13-0582]

Huang WS, Hsieh MC, Huang CY, Kuo YH, Tung SY, Shen CH, Hsieh YY, Teng CC, Lee KF, Chen TC, Lee KC, Kuo HC. The Association of CXCR4 Receptor 4 Mediated Signaling Pathway with Oxaliplatin-Resistant Human Colorectal Cancer Cells. *PLoS One* 2016; 11: e0159927 [PMID: 27668882 DOI: 10.1371/journal.pone.0159927]

Jin F, Ji H, Jia C, Brockmeier U, Herrmann DM, Metzen E, Zha Y, Chi B. Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIIF and CXCR4 in the colorectal cancer cell line SW1116. *PLoS ONE* 2016; 11: e0174161 [PMID: 24061744 DOI: 10.1371/journal.pone.0174161]

Jung K, Heishi T, Incio J, Huang Y, Beech EF, Pinter M, Ho WW, Kawaguchi K, Rahbani NN, Chung E, Kim JK, Clark JW,
Cabrero-de las Heras S et al. CXC chemokines in CRC

Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D. Targeting CXCXR4-dependent immunosuppressive Ly6C+ monocytes improves antiangiogenic therapy in colorectal cancer. Proc Natl Acad Sci USA 2017; 114: 10455-10460 [PMID: 28900008 DOI: 10.1073/pnas.1705741114]

49 Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MD, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-2213 [PMID: 16904016 DOI: 10.1084/jem.200525144]

50 Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR. The chemokine receptors CXCXR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-754 [PMID: 9466968 DOI: 10.1172/JCI1422]

51 Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162: 3549-3558 [PMID: 10092813]

52 Lal N, White BS, Goussous G, Pickles O, Mason MJ, Beggs AD, Tanierie P, Willcoxo BE, Guinne J, Middleton GW. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. Clin Cancer Res 2018; 24: 224-233 [PMID: 29061646 DOI: 10.1158/1078-0432.CCR-17-1090]

53 Kistner L, Doll D, Holtorf A, Nitsche U, Janssen KP. Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. Oncotarget 2017; 8: 8999-90012 [PMID: 29163806 DOI: 10.18632/oncotarget.21286]

54 Zumwalt TJ, Arnold M, Goel A, Boland CR. Active secretion of CXCXR10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget 2015; 6: 2981-2991 [PMID: 25671296 DOI: 10.18632/oncotarget.32035]

55 Wu Z, Huang X, Han X, Li Z, Zhu Q, Yan J, Yu S, Jin Z, Wang Z, Zheng Q, Wang Y. The chemokine CXLCL9 expression is associated with better prognosis for colorectal cancer patients. Biomed Pharmacother 2016; 78: 8-13 [PMID: 26898419 DOI: 10.1016/j.biopha.2015.12.021]

56 Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skothem RI, Lothe RA. ColoGuideEx: a robust gene classifier for prognosis of multiple human cancers defines an inflammatory cancer-associated molecular signature. Evol Biol Cancer 2014; 7: 27394-27407 [PMID: 27034164 DOI: 10.18632/oncotarget.8423]

57 Brackett CM, Kojoharoff B, Veith J, Greene KF, Burdelya L, Lau W, Wu H, Liu L, Su XY, Wang J, Chu ZH. Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer. Oncotarget 2016; 7: 28704-28717 [PMID: 27849017 DOI: 10.18632/oncotarget.8608]

58 Zeng YJ, Lai W, Wu H, Liu L, Xu HY, Wang J, Chu ZH. Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer. Oncotarget 2016; 7: 27394-27407 [PMID: 27034164 DOI: 10.18632/oncotarget.8423]

59 Yang H, Yamazaki T, Pietrocola F, Zitvogel L, Ma Y, Zeng YJ, Qin T, Sun S, Zhong WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One 2013; 8: e57911 [PMID: 23536776 DOI: 10.1371/journal.pone.0057911]

60 Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014; 32: 659-702 [PMID: 24655300 DOI: 10.1146/annurev-immunol-052713-120145]
